- Radiotherapy and immune checkpoint blockades: a snapshot in 2016
-
Koo T, Kim IA
- KMID: 2366045
- Radiat Oncol J.
- 2016 Dec;34(4):250-259.
- doi: 10.3857/roj.2016.02033
Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto's Thyroiditis
-
Kim H, Kim MJ, Song YS, Cho SW
- KMID: 2448989
- Int J Thyroidol.
- 2018 Nov;11(2):172-175.
- doi: 10.11106/ijt.2018.11.2.172
Anti-programmed cell death-1 (PD-1) humanized monoclonal antibody inhibits PD-1 activity by binding to the PD-1 receptor on T-cells and blocking PD-1 ligands and induces immune tolerance of cancer cells. It... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Nivolumab-induced Cutaneous Toxicity
-
Choi W, Myung KB, Hahn HJ, Cheong SH
- KMID: 2457689
- Korean J Dermatol.
- 2019 Aug;57(7):383-386.
Nivolumab is anti-programmed death 1 (PD1) receptor antibody, which can be used in the treatment of metastatic squamous cell cancer. By blocking the PD1 receptors on T cells, it enhances... -
- CITED
-
- Close
- SHARE
-
- Close
- Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
-
Braschi-Amirfarzan M, Tirumani S, Hodi FS, Nishino M
- KMID: 2468121
- Korean J Radiol.
- 2017 Feb;18(1):42-53.
- doi: 10.3348/kjr.2017.18.1.42
Over the past five years immune-checkpoint inhibitors have dramatically changed the therapeutic landscape of advanced solid and hematologic malignancies. The currently approved immune-checkpoint inhibitors include antibodies to cytotoxic T-lymphocyte antigen-4,... -
- CITED
-
- Close
- SHARE
-
- Close
- Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
-
Zhu X, Lang J
- KMID: 2413224
- J Gynecol Oncol.
- 2017 Sep;28(5):e64.
- doi: 10.3802/jgo.2017.28.e64
Programmed death-1 (PD-1) and its ligand are part of the immune checkpoint pathway that down-regulates effector T cells in immune response, thereby causing immune suppression. The PD-1/programmed death-ligand 1 (PD-L1)... -
- CITED
-
- Close
- SHARE
-
- Close
- Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
-
Kim KH, Kim CG, Shin EC
- KMID: 2471048
- Immune Netw.
- 2020 Feb;20(1):e8.
- doi: 10.4110/in.2020.20.e8
Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Management for Advanced Hepatocellular Carcinoma with Extrahepatic Metastasis by Autologous Natural Killer Cells Combined with Immune Checkpoint Inhibitor
-
Woo A, Kim EJ, Shin SY, Jeon HJ, Park H, Chon YE, Lee YB, Hwang SG, Rim KS, Lee JH
- KMID: 2409651
- J Liver Cancer.
- 2018 Mar;18(1):67-74.
- doi: 10.17998/jlc.18.1.67
Hepatocellular carcinoma (HCC) has extremely poor prognosis. Immunotherapy has emerged as a new treatment for a number of cancers. Adoptive immunotherapy is one of the important cancer immunotherapy, which relies... -
- CITED
-
- Close
- SHARE
-
- Close
- Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A
-
Cho H, Kang H, Kim CW, Kim HY, Jang JW, Yoon SK, Lee CD
- KMID: 2363975
- Gut Liver.
- 2016 Mar;10(2):288-294.
- doi: 10.5009/gnl14368
BACKGROUND/AIMS: The immunoregulatory molecules programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) are associated with the dysfunction of antiviral effector T-cells, which leads to T-cell exhaustion and... -
- CITED
-
- Close
- SHARE
-
- Close
- The Expression of Programmed Death-1 in Circulating CD4+ and CD8+ T Cells during Hepatitis B Virus Infection Progression and Its Correlation with Clinical Baseline Characteristics
-
Xu P, Chen YJ, Chen H, Zhu XY, Song HF, Cao LJ, Wang XF
- KMID: 1774547
- Gut Liver.
- 2014 Mar;8(2):186-195.
BACKGROUND/AIMS: Programmed death-1 (PD-1) expression was investigated in CD4+ and CD8+ T cells from hepatitis B virus (HBV)-infected patients at the chronic hepatitis B (CHB) infection, liver cirrhosis (LC), and... -
- CITED
-
- Close
- SHARE
-
- Close
- Immune checkpoint blockade therapy for bladder cancer treatment
-
Kim J
- KMID: 2426521
- Investig Clin Urol.
- 2016 Jun;57(Suppl 1):S98-S105.
- doi: 10.4111/icu.2016.57.S1.S98
Bladder cancer remains the most immunogenic and expensive malignant tumor in the United States today. As the 4th leading cause of death from cancer in United States, Immunotherapy blocking immune... -
- CITED
-
- Close
- SHARE
-
- Close
- Immune checkpoint inhibitors for urothelial carcinoma
-
Kim HS, Seo HK
- KMID: 2419411
- Investig Clin Urol.
- 2018 Sep;59(5):285-296.
- doi: 10.4111/icu.2018.59.5.285
Urothelial carcinoma (UC), originating in the bladder or upper urinary tract, is the most common histological type of cancer. Currently, platinum-based cytotoxic chemotherapy is the standard treatment for metastatic UC... -
- CITED
-
- Close
- SHARE
-
- Close
- Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
-
Cho JH, Zhou W, Choi YL, Sun JM, Choi H, Kim TE, Dolled-Filhart M, Emancipator K, Rutkowski , Kim J
- KMID: 2403478
- Cancer Res Treat.
- 2018 Jan;50(1):95-102.
- doi: 10.4143/crt.2016.591
PURPOSE: Data are limited on programmed death ligand 1 (PD-L1) expression in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We retrospectively evaluated the relationship between... -
- CITED
-
- Close
- SHARE
-
- Close
